Compare OVV & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVV | VTRS |
|---|---|---|
| Founded | 2020 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 17.2B |
| IPO Year | 2019 | 2019 |
| Metric | OVV | VTRS |
|---|---|---|
| Price | $58.37 | $14.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $58.35 | $13.50 |
| AVG Volume (30 Days) | 3.1M | ★ 8.0M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | 2.11% | ★ 3.24% |
| EPS Growth | ★ 13.54 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | $8,908,000,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $5.45 | $4.41 |
| Revenue Next Year | N/A | $1.96 |
| P/E Ratio | $11.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.91 | $8.19 |
| 52 Week High | $62.60 | $16.47 |
| Indicator | OVV | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 60.66 |
| Support Level | $36.80 | $12.90 |
| Resistance Level | $62.60 | $15.22 |
| Average True Range (ATR) | 1.37 | 0.40 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 99.66 | 74.86 |
Ovintiv Inc is a North American oil and natural gas exploration and production company focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs, and natural gas. The company has two operating segments: USA Operations and Canadian Operations. USA Operations include the exploration, development, production, and marketing of oil, NGLs, natural gas, and other related activities within the United States. Canadian Operations include the exploration, development, production, and marketing of oil, NGLs, natural gas, and other related activities within Canada. The company generates the majority of its revenue from USA Operations.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.